Perspective Therapeutics (CATX) Assets Average (2011 - 2026)
Perspective Therapeutics (CATX) posted Assets Average of $338.9 million for Q1 2026, up 20.64% sequentially from $280.9 million in Q4 2025, and up 1.09% YoY from $335.2 million in Q1 2025.
Perspective Therapeutics (CATX) Assets Average (2011 - 2026) Analysis & Trends
Perspective Therapeutics has reported Assets Average for 15 years, with the latest figure at $338.9 million in Q1 2026.
- Quarterly Assets Average rose 1.09% year-over-year to $338.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $338.9 million (up 1.09% YoY) and the FY2025 annual result came in at $304.0 million, up 38.52% from the prior year.
- Assets Average climbed to $338.9 million in Q1 2026 per CATX's latest filing, from $280.9 million in the prior quarter.
- Over five years, Assets Average peaked at $388.5 million in Q3 2024 and troughed at $60.3 million in Q4 2022.
- A 5-year average of $208.5 million and a median of $188.1 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average surged 251.35% in 2024, then declined 23.28% in 2025.
- Over 5 years, Assets Average stood at $60.3 million in 2022, then surged by 72.77% to $104.2 million in 2023, then soared by 251.35% to $366.1 million in 2024, then decreased by 23.28% to $280.9 million in 2025, then grew by 20.64% to $338.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $338.9 million, $280.9 million, and $302.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.19 Bn | 194.59 Bn | 7.27 Bn | 109.82 Bn |
| 2 | Stryker | 129.95 Bn | 126.47 Bn | 4.50 Bn | 47.11 Bn |
| 3 | Medtronic | 120.06 Bn | 110.84 Bn | 6.41 Bn | 92.26 Bn |
| 4 | Boston Scientific | 74.14 Bn | 73.60 Bn | 3.85 Bn | 44.78 Bn |
| 5 | Edwards Lifesciences | 52.74 Bn | 48.49 Bn | 1.35 Bn | 13.59 Bn |
| 6 | Dexcom | 34.60 Bn | 32.65 Bn | 830.00 Mn | 6.54 Bn |
| 7 | GE HealthCare Technologies | 34.20 Bn | 32.10 Bn | 2.18 Bn | 37.19 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.13 Bn | 4.55 Bn | 31.48 Bn |
| 9 | Steris | 23.25 Bn | 22.77 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Perspective Therapeutics | 388.50 Mn | 388.50 Mn | - | 401.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401.40 Mn |
| Mar 31, 2026 | 338.87 Mn |
| Dec 31, 2025 | 280.90 Mn |
| Sep 30, 2025 | 302.78 Mn |
| Jun 30, 2025 | 320.04 Mn |
| Mar 31, 2025 | 335.23 Mn |
| Dec 31, 2024 | 366.13 Mn |
| Sep 30, 2024 | 388.54 Mn |
| Jun 30, 2024 | 332.10 Mn |
| Mar 31, 2024 | 188.09 Mn |
| Dec 31, 2023 | 104.20 Mn |
| Sep 30, 2023 | 115.33 Mn |
| Jun 30, 2023 | 123.90 Mn |
| Mar 31, 2023 | 92.87 Mn |
| Dec 31, 2022 | 60.31 Mn |
| Sep 30, 2022 | 63.49 Mn |
| Jun 30, 2022 | 65.28 Mn |
| Mar 31, 2022 | 66.68 Mn |
| Dec 31, 2021 | 67.98 Mn |
| Sep 30, 2021 | 69.56 Mn |